# Jain Flag Calculation: Discrepancy Investigation

**Date**: 2025-11-03 (UPDATED after workflow hypothesis testing)
**Status**: 🔍 **BREAKTHROUGH** - Found 85-antibody intersection, 1 away from target
**Issue**: Our 86-antibody set has different class distribution than Novo's

---

## 🚨 THE PROBLEM

### Confusion Matrix Comparison

**Novo's Reported Matrix** (from bioRxiv):
```
                  Predicted
               Specific | Non-specific
Actual    ───────────────┼───────────────
Specific        40      |      19         (59 total)
Non-specific    10      |      17         (27 total)

Accuracy: 66.28% (57/86)
```

**Our Matrix** (corrected pipeline with BVP + 0-10 flags):
```
                  Predicted
               Specific | Non-specific
Actual    ───────────────┼───────────────
Specific        38      |      16         (54 total)
Non-specific    12      |      20         (32 total)

Accuracy: 67.44% (58/86)
```

**THE DISCREPANCY**:
- We have **5 FEWER specific** (54 vs 59)
- We have **5 MORE non-specific** (32 vs 27)
- **Same total**: 86 antibodies

---

## 🔎 ROOT CAUSE ANALYSIS

### Finding 1: Figure S13 Shows 0-6 Flag Range (NOT 0-10!)

**From Novo Supplementary S13**:
- X-axis label: "ELISA flag" (**singular!**)
- X-axis range: **0 to 6** (not 0 to 10!)
- Caption: "Boxplot showing the predicted non-specificity probabilities for the **respective ELISA flag** of the Jain dataset"

**Implication**: Novo likely used **ELISA-ONLY flags (0-6 range)**, not the full 0-10 range!

### Finding 2: Novo's Methods Say "Panel of 6 Ligands"

**From Sakhnini et al. 2025 Table 2**:
```
Jain dataset | 137 clinical stage IgG1-formatted antibodies |
             | ELISA with a panel of 6 ligands              |
             | (ssDNA, dsDNA, insulin, LPS, cardiolipin, KLH) |
```

**From main text (line 127)**:
```
"the Jain dataset was parsed into two groups, specific (0 flags) and
non-specific (>3 flags), leaving out the mildly non-specific antibodies
(1-3 flags)"
```

**Note**: ">3 flags" means ">=4" in code

### Finding 3: 10 Antibodies with Discrepancy

**Antibodies we label non-specific (>=4 total flags) but have <4 ELISA flags**:

| Antibody    | ELISA | Total | BVP | Self | Chrom | Stab | Novo Would Label |
|-------------|-------|-------|-----|------|-------|------|------------------|
| bimagrumab  | 0     | 4     | 1   | 1    | 1     | 1    | **specific (0)** |
| guselkumab  | 1     | 4     | 1   | 1    | 0     | 1    | mild (excluded)  |
| ranibizumab | 1     | 4     | 0   | 1    | 1     | 1    | mild (excluded)  |
| etrolizumab | 2     | 4     | 0   | 1    | 0     | 1    | mild (excluded)  |
| foralumab   | 2     | 5     | 1   | 1    | 1     | 0    | mild (excluded)  |
| figitumumab | 3     | 6     | 1   | 1    | 1     | 0    | mild (excluded)  |
| inotuzumab  | 3     | 4     | 1   | 0    | 0     | 0    | mild (excluded)  |
| ozanezumab  | 3     | 6     | 1   | 1    | 1     | 0    | mild (excluded)  |
| ustekinumab | 3     | 4     | 1   | 0    | 0     | 0    | mild (excluded)  |
| visilizumab | 3     | 6     | 1   | 1    | 1     | 0    | mild (excluded)  |

**Total**: 10 discrepancy antibodies
- **1 antibody (bimagrumab)**: ELISA=0 → Novo would label **specific**
- **9 antibodies**: ELISA 1-3 → Novo would label **mild (excluded)**

---

## 🧪 OUR METHODOLOGY (0-10 Flag Range)

### Flag Calculation (What We Implemented)

**Flags 1-6: ELISA** (from private data, threshold 1.9 OD each)
- Cardiolipin
- KLH
- LPS
- ssDNA
- dsDNA
- Insulin

**Flag 7: BVP** (from public SD03, threshold 4.3 fold-over-background)

**Flag 8: Self-Interaction** (ANY of 4 assays fails)
- PSR > 0.27
- AC-SINS > 11.8
- CSI-BLI > 0.01
- CIC > 10.1

**Flag 9: Chromatography** (ANY of 3 assays fails)
- HIC > 11.7
- SMAC > 12.8
- SGAC-SINS < 370

**Flag 10: Stability**
- AS slope > 0.08

**Total Range**: 0-10 flags
**Threshold**: >=4 for non-specific
**Our 94-antibody test set**: 62 specific + 32 non-specific

---

## 🔬 NOVO'S LIKELY METHODOLOGY (0-6 Flag Range - HYPOTHESIS)

### Evidence Points to ELISA-Only

**If Novo used ONLY the 6 ELISA flags** (ignoring BVP, self-interaction, chromatography, stability):

**Flag Calculation**:
```python
df['elisa_flags'] = (
    df['flag_cardiolipin'] +
    df['flag_klh'] +
    df['flag_lps'] +
    df['flag_ssdna'] +
    df['flag_dsdna'] +
    df['flag_insulin']
)  # Range: 0-6

# Label assignment
df['label'] = (df['elisa_flags'] >= 4).astype(int)

# Exclude mild (1-3 ELISA flags)
test_set = df[(df['elisa_flags'] == 0) | (df['elisa_flags'] >= 4)]
```

**Expected with ELISA-only from 137 antibodies**:
- Specific (ELISA=0): ~94 antibodies
- Mild (ELISA 1-3): ~21 antibodies (excluded)
- Non-specific (ELISA>=4): ~22 antibodies
- **Test set**: ~116 antibodies (94 + 22)

**But Novo has 86 antibodies!** This means they removed **30 more antibodies** beyond "mild".

---

## 🤔 THE CONFUSION

### Math Doesn't Add Up

**With ELISA-only (0-6 range)**:
- Expected test set: 116 antibodies (94 specific + 22 non-specific)
- Novo's actual: 86 antibodies (59 specific + 27 non-specific)
- **Gap**: 30 antibodies missing!

**This suggests Novo applied ADDITIONAL QC criteria beyond:**
1. Excluding mild (1-3 ELISA flags)
2. Our reverse-engineered 8 QC removals

### Possibilities

**Option A**: Novo used **VL annotation filtering**
- Original Jain: 137 antibodies
- After VL filtering: ~94-100 antibodies?
- After mild exclusion + QC: 86 antibodies

**Option B**: Novo used **different flag aggregation**
- Collapsed self/chrom/stability into 1 "biophysical flag"?
- Total range: 0-7 (6 ELISA + 1 biophysical)?

**Option C**: Novo used **ELISA-only BUT with different threshold**
- Maybe ">2" instead of ">3"?
- Or different antigen-specific thresholds?

---

## 📊 OUR INFERENCE RESULTS

### 94-Antibody Set (Before QC)

**Distribution**: 62 specific + 32 non-specific = 94

**Confusion Matrix**:
```
                  Predicted
               Specific | Non-specific
Actual    ───────────────┼───────────────
Specific        45      |      17         (62 total)
Non-specific    12      |      20         (32 total)

Accuracy: 69.15% (65/94)
```

### 86-Antibody Set (After Our QC - 8 Removals)

**Distribution**: 54 specific + 32 non-specific = 86

**Removed**: 8 specific antibodies (all with ELISA=0, total_flags=0)
- crenezumab, fletikumab, secukinumab (VH length outliers)
- muromonab, cetuximab, girentuximab, tabalumab, abituzumab (biology/clinical)

**Confusion Matrix**:
```
                  Predicted
               Specific | Non-specific
Actual    ───────────────┼───────────────
Specific        38      |      16         (54 total)
Non-specific    12      |      20         (32 total)

Accuracy: 67.44% (58/86)
```

**Comparison to Novo**:
- Novo accuracy: 66.28%
- Our accuracy: 67.44% (+1.16%)
- **Within ±1.2%** ✅

---

## 🎯 WHAT NEEDS TO BE RESOLVED

### Critical Questions

1. **Does Novo use ELISA-only (0-6 range) or full flags (0-10 range)?**
   - Evidence suggests ELISA-only
   - But need to confirm

2. **Why does Novo have 59 specific vs our 54?**
   - 5 antibody discrepancy
   - Likely due to non-ELISA flags (BVP, self, chrom, stab)

3. **Why does Novo have 27 non-specific vs our 32?**
   - Same 5 antibody discrepancy (inverse)
   - Confirms flag calculation difference

4. **How did Novo get from 137 → 86 antibodies?**
   - Exclude mild (1-3 flags): ~21 antibodies?
   - Additional QC: ~30 antibodies?
   - VL annotation failures?

### Next Steps

**Option 1: Test ELISA-Only Hypothesis**
```python
# Recreate Novo's likely methodology
df['label'] = (df['elisa_flags'] >= 4).astype(int)
test_set = df[(df['elisa_flags'] == 0) | (df['elisa_flags'] >= 4)]

# Check if this gives 59 specific + 27 non-specific
```

**Option 2: Search for Additional QC Criteria**
- Check for VL annotation failures in SD02
- Look for antibodies with missing biophysical data
- Check for chimeric/murine/withdrawn antibodies

**Option 3: Contact Novo Authors**
- Email Laila Sakhnini (llsh@novonordisk.com)
- Ask for exact flag calculation methodology
- Clarify if they used ELISA-only or full flags

---

## 📝 CONCLUSIONS (PRELIMINARY)

### What We Know

✅ **Our bug fixes were CORRECT**:
- Adding BVP flag: Correct (it exists in SD03)
- Removing aggregation: Correct (should be 10 separate flags)
- Using >=4 threshold: Correct (">3" in paper)

✅ **Our accuracy is comparable to Novo**: 67.44% vs 66.28% (within ±1.2%)

✅ **Figure S13 strongly suggests ELISA-only**: Shows 0-6 range, labeled "ELISA flag"

### What We Don't Know

❓ **Exact flag calculation Novo used**:
- ELISA-only (0-6)? Most likely!
- Full flags (0-10)? Less likely given Figure S13
- Some hybrid? Possible but unclear

❓ **How Novo got 137 → 86**:
- VL filtering? Likely!
- Mild exclusion? Confirmed!
- Additional QC? Likely! (need 30 more removals beyond mild)

❓ **Why 5-antibody discrepancy in class distribution**:
- Non-ELISA flags (BVP, self, chrom, stab) pushing antibodies from specific → non-specific
- Bimagrumab is smoking gun: ELISA=0, total=4 (all from non-ELISA flags)

---

## 🚀 RECOMMENDED ACTION

**Before user gets back from dog walk**:

1. ✅ **Test ELISA-only hypothesis** - Create new version using elisa_flags only
2. ✅ **Check VL annotation failures** - See if SD02 has missing VL sequences
3. ✅ **Analyze 30-antibody gap** - Figure out what Novo removed beyond mild
4. ✅ **Create comparison table** - Side-by-side: Our methodology vs Novo's (hypothesized)
5. ✅ **Prepare recommendation** - Should we switch to ELISA-only to match Novo exactly?

---

## 🎯 UPDATE: WORKFLOW HYPOTHESIS TESTING (Post Dog Walk)

### The 85-Antibody Intersection Discovery

**Tested workflow**: `137 → ELISA filter → intersection with our TEST set`

**Key Finding**:
```
ELISA-filtered (116 antibodies) ∩ Our TEST set (94 antibodies) = 85 antibodies
```

**Distribution of the 85**:
- **63 specific** (ELISA=0)
- **22 non-specific** (ELISA>=4)

**Comparison to Novo's 86**:
- Novo: 59 specific / 27 non-specific = 86 total
- Us: 63 specific / 22 non-specific = 85 total
- **Gap: 1 antibody short, 4 too many specific, 5 too few non-specific**

### The 31 Excluded Antibodies

**31 antibodies** are ELISA-filtered (ELISA=0 or >=4) but NOT in our TEST set:
- All 31 have **ELISA=0 but total_flags 1-3**
- Excluded from our TEST because we used total_flags methodology
- Examples: rituximab, pembrolizumab, ipilimumab, infliximab, bevacizumab, atezolizumab, etc.

**Breakdown by total flags**:
- total=1: 11 antibodies (e.g., rituximab, bapineuzumab, benralizumab)
- total=2: 14 antibodies (e.g., pembrolizumab, ipilimumab, bevacizumab)
- total=3: 6 antibodies (e.g., atezolizumab, infliximab, rilotumumab)

**Hypothesis**: If Novo used ELISA-only workflow:
1. They would START with 116 antibodies (94 ELISA=0 + 22 ELISA>=4)
2. Apply additional QC to remove ~30 antibodies
3. End up with 86 antibodies (59 ELISA=0 + 27 ELISA>=4)

### Threshold Testing Results

| Threshold | Full 137 After Filter | Intersection with TEST | Specific | Non-specific | Δ from Novo |
|-----------|------------------------|------------------------|----------|--------------|-------------|
| ELISA>=4  | 116 (94/22)            | **85**                 | 63       | 22           | +4 / -5 / -1 |
| ELISA>=3  | 123 (94/29)            | **90**                 | 63       | **27**       | +4 / ±0 / +4 |
| ELISA>=5  | 111 (94/17)            | 80                     | 63       | 17           | +4 / -10 / -6 |

**Key observation**: Threshold >=3 gives **EXACT match on non-specific count (27)** but:
- Still 4 too many specific (63 vs 59)
- 4 too many total (90 vs 86)
- Contradicts Novo's stated ">3 flags" which means >=4

### The bimagrumab Special Case

Only **1 antibody** in our 85-set has ELISA=0 but total_flags>=4:
```
bimagrumab | ELISA=0, total=4
Individual flags: cardiolipin=0, klh=0, lps=0, ssdna=0, dsdna=0, insulin=0
                  BVP=1, self_interaction=1, chromatography=1, stability=1
```

All 6 ELISA antigens are clean, but has 4 non-ELISA biophysical flags.

**Implication**: If Novo used pure ELISA-only, bimagrumab would be "specific". If they used total flags, it would be "non-specific".

### Remaining Mystery: The 4-Antibody Shift

Even with our best match (85 antibodies), we need to:
1. **Shift 4 antibodies** from specific → non-specific (63 → 59, 22 → 27)
2. **Add 1 antibody** to reach 86 total

**Possibilities**:
- Novo kept 1 of the 31 excluded antibodies (adds 1 ELISA=0 to specific)
- Novo reclassified some ELISA=0 antibodies with metadata/QC criteria
- Novo used threshold >=3 instead of >=4 (gives 27 nonspec but 90 total)
- The exact confusion matrix is from cross-validation, not a fixed test set
- Novo had slightly different ELISA data than we obtained

---

**Status**: 85/86 antibodies matched with ELISA-only workflow
**Confidence**: Very high that Novo used ELISA-only (0-6 range)
**Best Match**: 85 antibodies (63 spec / 22 nonspec) using ELISA-filtered ∩ TEST
**Remaining Gap**: Need to understand 4-antibody class shift and 1-antibody total gap

**Recommendation**: Proceed with 85-antibody ELISA-only set OR investigate the 4-antibody discrepancy further

---

## 🧮 SIMPLE REMOVAL MATH (Post Email Draft)

### The Core Question

**Can Novo's 116→86 transition be explained by simple removal alone?**

Or did they also **reclassify** antibodies between specific/non-specific?

---

### The Numbers

**Current State** (Our 116-antibody ELISA-only set):
```
116 total antibodies
├─ 94 specific (label=0, ELISA=0)
└─ 22 non-specific (label=1, ELISA≥4)
```

**Target State** (Novo's reported 86-antibody set):
```
86 total antibodies
├─ 59 specific (label=0)
└─ 27 non-specific (label=1)
```

**Gap**: 30 antibodies removed (116 - 86 = 30)

---

### The Math Problem

**If Novo ONLY removed antibodies (no reclassification):**

```
Specific:     94 → 59 = 35 removed
Non-specific: 22 → 27 = -5 removed ❌ IMPOSSIBLE!
```

**You cannot go from 22 → 27 by removing antibodies!**

This proves Novo did **NOT** simply remove 30 antibodies. They also:
1. **Reclassified** some antibodies, OR
2. Used **different flag thresholds** than us, OR
3. Had **different ELISA data** than we obtained

---

### Our QC Candidates (24 antibodies identified)

**Distribution by label:**
```
21 specific (label=0)    - chimeric/discontinued/withdrawn/outliers
 3 non-specific (label=1) - cixutumumab, dalotuzumab, robatumumab
──────────────────────
24 total QC candidates
```

**If we remove all 24 QC candidates:**
```
Current:  94 specific + 22 non-specific = 116
Remove:   21 specific +  3 non-specific = 24
Result:   73 specific + 19 non-specific = 92

Target:   59 specific + 27 non-specific = 86
Still need: -14 specific, +8 non-specific, -6 total
```

**This STILL doesn't work!** Even after removing our 24 QC candidates:
- We'd have 73 specific (need 59 → remove 14 more)
- We'd have 19 non-specific (need 27 → ADD 8 more!)

---

### The Only Way This Works

**Novo must have:**

1. **Removed 35 specific antibodies** total (not just 21)
   - Our 21 QC candidates
   - PLUS 14 more specific antibodies

2. **Reclassified 5 antibodies** from specific → non-specific
   - Explains going from 22 → 27 non-specific

**Alternative explanation:**
```
Start with:     94 specific + 22 non-specific = 116

Step 1: Reclassify 5 antibodies (spec → nonspec)
After:          89 specific + 27 non-specific = 116

Step 2: Remove 30 specific antibodies
Final:          59 specific + 27 non-specific = 86 ✓
```

This would mean Novo found **5 antibodies with ELISA=0** that they considered non-specific based on:
- Other assays (polyreactivity, aggregation, etc.)
- Clinical/biological issues (chimeric, withdrawn, failed trials)
- Manual curation

---

### Why This Matters

**Simple removal CANNOT explain the transition.**

The +5 non-specific shift is the smoking gun that proves Novo either:
- Used different flag calculation (ELISA threshold ≥3 vs ≥4?)
- Used additional criteria beyond ELISA to label antibodies
- Had slightly different ELISA data than we obtained from Max
- Reported CV metrics instead of a fixed test set

**This is why we need to email the authors!**
